Investors urged to seek help for losses in DexCom case
- Faruqi & Faruqi, LLP is investigating claims on behalf of DexCom investors.
- Investors who suffered losses exceeding $100,000 are encouraged to contact James Wilson directly.
- The securities litigation partner is offering options to discuss potential losses.
New York, New York—Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating potential claims against DexCom, Inc. (NASDAQ:DXCM) following a significant drop in the company's stock price. Securities Litigation Partner James (Josh) Wilson is reaching out to investors who incurred losses exceeding $100,000 between January 8, 2024, and July 25, 2024, encouraging them to discuss their legal options. Interested parties can contact Wilson directly at 877-247-4292 or 212-983-9330. The firm has highlighted an impending deadline of October 21, 2024, for investors to seek the role of lead plaintiff in a federal securities class action against DexCom. The complaint alleges that the company made materially false and misleading statements and failed to disclose critical adverse information regarding its business operations and future prospects. On July 25, 2024, DexCom reported disappointing financial results for the second quarter and lowered its revenue guidance for the fiscal year, leading to a dramatic stock price decline from $107.85 to $64.00 per share—an approximate 40.66% drop in just one day. Faruqi & Faruqi encourages any individuals with information regarding DexCom's conduct, including whistleblowers and former employees, to reach out to the firm. For more details on the class action, investors can visit www.faruqilaw.com/DXCM or contact Josh Wilson directly.